WHERE YOU GO, WHEN YOU NEED TO KNOW!
105 East Wood Street
Paris, TN 38242
731-641-9944
Colon AiQ
The alternated way to test for colon cancer by blood draw other than stool studies. This does not need to replace your colonoscopy.
Many people are hesitant to undergo colon cancer screening, leading to low screening rates in the U.S. Colon AiQ offers a simple blood test using advanced DNA methylation technology to detect tumor DNA specific to colon cancer in its earliest stages.The test focuses on 5 specific DNA regions linked to colorectal cancer. Its patented chemistry accurately detects cancer signals in these biomarkers using AI-powered analysis. A 'positive' result suggests consulting a healthcare provider for further testing, including a colonoscopy.
The rising incidence of colon cancer, including rectal cancers, among younger adults is a matter of concern. Over the past three decades, there has been a notable 51% increase in young-onset colorectal cancer, particularly among women. Consequently, the U.S. Preventive Services Task Force has revised its guidelines, recommending colorectal cancer screening for average-risk adults to commence at the age of 45.
Beginning at age 45, all average-risk adults should undergo colorectal cancer (CRC) screening, as recommended by the U.S. Preventive Services Task Force in 2021. However, due to widespread reluctance, millions of eligible adults between the ages of 45 and 75 have never been screened. Individuals at higher risk should consider starting screenings at age 40 or earlier based on specific risk factors.
Individuals aged 75 and above should also consider undergoing colorectal cancer (CRC) screening. This recommendation is made on a case-by-case basis, taking into consideration the patient's overall health, prior screening history, and personal preferences. It's important to note that the risk of developing CRC increases with age, with the average age for a diagnosis of colorectal cancer being 66.
Early screening is crucial in combating colon cancer. This non-invasive blood-based test is specifically designed as a screening tool for adults aged 45 to 75 and those at higher risk. It is not recommended for individuals who have undergone a recent blood transfusion or bone marrow transplant, are pregnant, have immediate family members who are pregnant, or have recently received cancer treatment.
It's important to know your family history. If you have a family history of cancer, it's crucial to get screened from the age of 40 or 10 years before the youngest case in your immediate family, whichever comes first. A family history of colorectal cancer can include a diagnosis in a parent, sibling, child under 60, or multiple second-degree relatives. The risk is higher if any of these relatives were diagnosed before the age of 45.
DNA Methylation Signals is a groundbreaking test that detects faint tumor signals specific to colon cancer and its precursor polyps, Advanced Adenoma, in a person’s blood. Using patented DNA Methylation technology, the test can identify small traces of Tumor Cell-Free DNA in the blood, even at incredibly low concentrations. This high sensitivity makes it an effective tool for early stage cancer detection without the need for invasive procedures or stool samples. This test does not need to be a replacement for colonoscopy.